Evaluating lung ultrasound after surfactant treatments in preterm babies
Evaluation of Serial Lung Ultrasound Data After Surfactant Treatments Applied With Different Methods in Preterm Babies
This study tests how different ways of giving surfactant treatment affect lung health in preterm babies with breathing problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 68 (estimated) |
| Ages | 1 Day to 5 Days |
| Sex | All |
| Sponsor | Konya City Hospital Academic / other |
| Locations | 1 site (Konya, Karatay) |
| Trial ID | NCT06880016 on ClinicalTrials.gov |
What this trial studies
This study investigates how different methods of surfactant administration affect lung ultrasound findings in preterm infants diagnosed with respiratory distress syndrome (RDS). Conducted in a neonatal intensive care unit, the research utilizes lung ultrasound as a diagnostic tool, which has become increasingly popular due to its high specificity and sensitivity. The study aims to compare the outcomes of surfactant treatments administered through endotracheal tubes versus less invasive methods. By monitoring serial lung ultrasound data, the study seeks to enhance understanding of treatment efficacy in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are preterm infants born before 32 weeks of gestation who require surfactant therapy for RDS.
Not a fit: Patients who may not benefit from this study include those with congenital heart disease or syndromic appearances, as well as infants born after 32 weeks of gestation.
Why it matters
Potential benefit: If successful, this study could improve treatment protocols for preterm infants with respiratory distress syndrome, leading to better health outcomes.
How similar studies have performed: Other studies have shown promising results using lung ultrasound for diagnosing and managing respiratory distress syndrome in neonates, indicating that this approach is both relevant and potentially effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Infants of families who agree to participate in the study * Preterm infants born before 32 weeks of gestation requiring surfactant therapy due to an RDS diagnosis. Exclusion Criteria: * Infants whose families did not provide consent * Infants with a syndromic appearance or congenital heart disease * Preterm infants born after 32 weeks of gestation
Where this trial is running
Konya, Karatay
- Melek Buyukeren — Konya, Karatay, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Melek Buyukeren — Konya City Hospital
- Study coordinator: Melek Buyukeren
- Email: melekbuyukeren@gmail.com
- Phone: +903323105000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.